1. history of influenza or acute respiratory viral infection (arvi) within 2 months before the start of the trial. 2. a serious post-vaccination reaction (temperature above 40 °c, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination). 3. fever, cough, and shortness of breath within 30 days before vaccination. 4. history of covid-19. 5. positive result of the covid-19 pcr test. 6. body temperature ≥ 37,0°c. 7. history of allergies. 8. any vaccination within 30 days before the screening. 9. history of leukemia, tuberculosis, cancer, autoimmune diseases. 10. history of quincke's edema. 11. positive blood test results for hiv, syphilis, hepatitis b/c. 12. volunteers who received immunoglobulin during the last three months before the trial. 13. history of long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs for six months before the trial. 14. treatment with glucocorticosteroids, including in small doses, as well as local use of drugs containing steroids (\> 10 mg of prednisolone or its equivalent for more than 14 days before the screening). 15. history of any confirmed or suspected immunosuppressive or immunodeficiency condition. 16. history of splenectomy. 17. history of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, the gastrointestinal tract, liver, kidneys, hematopoietic or immune systems, mental disease in the acute stage or in the decompensation stage. 18. transfusion of blood or blood components within 4 months before screening. 19. history of acute and chronic infectious diseases. 20. consumption of more than 10 units of alcohol per week or history of alcohol addiction, drug addiction or abuse of pharmaceutical products. 21. smoking of more than 10 cigarettes per day. 22. participation in another clinical trial within the last 90 days. 23. pregnancy or lactation. 24. coagulopathy, hemophilia, bleeding disorder. 25. participation in stage i of this trial (for volunteers of stage ii). 26. transfusion of covid-19 convalescent plasma within 14 days before the screening, covid-19 vaccination less than 30 days before the screening

1. history of influenza or acute respiratory viral infection (arvi) within 2 months before the start of the trial. 2. a serious post-vaccination reaction (temperature above 40 °c, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination). 3. fever, cough, and shortness of breath within 30 days before vaccination. 4. history of covid-19. 5. positive result of the covid-19 pcr test. 6. body temperature ≥ 37,0°c. 7. history of allergies. 8. any vaccination within 30 days before the screening. 9. history of leukemia, tuberculosis, cancer, autoimmune diseases. 10. history of quincke's edema. 11. positive blood test results for hiv, syphilis, hepatitis b/c. 12. volunteers who received immunoglobulin during the last three months before the trial. 13. history of long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs for six months before the trial. 14. treatment with glucocorticosteroids, including in small doses, as well as local use of drugs containing steroids (\> 10 mg of prednisolone or its equivalent for more than 14 days before the screening). 15. history of any confirmed or suspected immunosuppressive or immunodeficiency condition. 16. history of splenectomy. 17. history of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, the gastrointestinal tract, liver, kidneys, hematopoietic or immune systems, mental disease in the acute stage or in the decompensation stage. 18. transfusion of blood or blood components within 4 months before screening. 19. history of acute and chronic infectious diseases. 20. consumption of more than 10 units of alcohol per week or history of alcohol addiction, drug addiction or abuse of pharmaceutical products. 21. smoking of more than 10 cigarettes per day. 22. participation in another clinical trial within the last 90 days. 23. pregnancy or lactation. 24. coagulopathy, hemophilia, bleeding disorder. 25. participation in stage i of this trial (for volunteers of stage ii). 26. transfusion of covid-19 convalescent plasma within 14 days before the screening, covid-19 vaccination less than 30 days before the screening

history of influenza or acute respiratory viral infection (arvi) within 2 months before the start of the trial. a serious post-vaccination reaction (temperature above 40 °c, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination). fever, cough, and shortness of breath within 30 days before vaccination. history of covid-19. positive result of the covid-19 pcr test. body temperature ≥ 37,0°c. history of allergies. any vaccination within 30 days before the screening. history of leukemia, tuberculosis, cancer, autoimmune diseases. history of quincke's edema. positive blood test results for hiv, syphilis, hepatitis b/c. volunteers who received immunoglobulin during the last three months before the trial. history of long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs for six months before the trial. treatment with glucocorticosteroids, including in small doses, as well as local use of drugs containing steroids (> 10 mg of prednisolone or its equivalent for more than 14 days before the screening). history of any confirmed or suspected immunosuppressive or immunodeficiency condition. history of splenectomy. history of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, the gastrointestinal tract, liver, kidneys, hematopoietic or immune systems, mental disease in the acute stage or in the decompensation stage. transfusion of blood or blood components within 4 months before screening. history of acute and chronic infectious diseases. consumption of more than 10 units of alcohol per week or history of alcohol addiction, drug addiction or abuse of pharmaceutical products. smoking of more than 10 cigarettes per day. participation in another clinical trial within the last 90 days. pregnancy or lactation. coagulopathy, hemophilia, bleeding disorder. participation in stage i of this trial (for volunteers of stage ii). transfusion of covid-19 convalescent plasma within 14 days before the screening, covid-19 vaccination less than 30 days before the screening

history of influenza or acute respiratory viral infection (arvi) within 2 months before the start of the trial. a serious post-vaccination reaction (temperature above 40 °c, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination). fever, cough, and shortness of breath within 30 days before vaccination. history of covid-19. positive result of the covid-19 pcr test. body temperature ≥ 37,0°c. history of allergies. any vaccination within 30 days before the screening. history of leukemia, tuberculosis, cancer, autoimmune diseases. history of quincke's edema. positive blood test results for hiv, syphilis, hepatitis b/c. volunteers who received immunoglobulin during the last three months before the trial. history of long-term use (more than 14 days) of immunosuppressants or other immunomodulatory drugs for six months before the trial. treatment with glucocorticosteroids, including in small doses, as well as local use of drugs containing steroids (> 10 mg of prednisolone or its equivalent for more than 14 days before the screening). history of any confirmed or suspected immunosuppressive or immunodeficiency condition. history of splenectomy. history of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, the gastrointestinal tract, liver, kidneys, hematopoietic or immune systems, mental disease in the acute stage or in the decompensation stage. transfusion of blood or blood components within 4 months before screening. history of acute and chronic infectious diseases. consumption of more than 10 units of alcohol per week or history of alcohol addiction, drug addiction or abuse of pharmaceutical products. smoking of more than 10 cigarettes per day. participation in another clinical trial within the last 90 days. pregnancy or lactation. coagulopathy, hemophilia, bleeding disorder. participation in stage i of this trial (for volunteers of stage ii). transfusion of covid-19 convalescent plasma within 14 days before the screening, covid-19 vaccination less than 30 days before the screening